This is a working overview of peptidase, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Springer's lab screened for such activity in cell line supernatants, purified and sequenced the protein, and found that stromal derived factor (SDF-1), previously defined as a growth factor for B cells, was a potent chemoattractant for both B and T cells. SDF-1 activated an orphan GPCR, later named CXCR4, which was also the co-receptor for T-cell-tropic HIV; SDF-1 further blocked infection of T cells by HIV. SDF-1 (CXCL12) is also a chemoattractant for CD34+ hematopoietic stem cells and regulates their movement from bone marrow to the bloodstream. Based on these discoveries, plerixafor (Mozobil) was developed as an antagonist of CXCR4 and is approved, in combination with filgrastim, for use in mobilizing hematopoietic stem cells in patients with multiple myeloma or non-Hodgkin lymphoma. In later retrospective discussion, Springer framed the three steps in leukocyte emigration into inflammatory sites as an “area code” model, emphasizing that each step requires a cognate receptor–ligand interaction and therefore provides multiple intervention points (selectins and ligands; GPCRs and ligands; integrins including LFA-1, α4β1, α4β7 and endothelial ligands). He argued that the size of the target space exceeded what could be pursued in an academic laboratory and helped motivate company formation.
In 2009, IGN named Newell one of the top 100 game creators, writing that it was "almost impossible to gauge" Valve's influence on game design, technology and the video games industry. In December 2010, Forbes listed Newell as "A Name You Need to Know", primarily for his work on Steam and partnerships with multiple major developers. In 2013, Newell was added to the Academy of Interactive Arts & Sciences Hall of Fame and received the BAFTA Fellowship for his contributions to the video game industry. According to Josh Weier, the project lead for Portal 2 (2011), Newell became less involved in game development after Portal 2 as many developers would blindly agree with his ideas due to his position. As of 2024, Newell had become less involved in Valve and was spending more time on personal projects.
==== Intracrine actions of PTHrP in cardiac cells ==== PTHrP exists in multiple isoforms, with some retained intracellularly rather than secreted. In cardiac myocytes and vascular smooth muscle cells, intracrine PTHrP is known to localize within the nucleus, where it regulates gene transcription, modulates cell proliferation, and affects intracellular calcium handling. One of the hallmark intracrine functions of PTHrP is its ability to influence angiogenesis. Studies have shown that nuclear PTHrP interacts with ribosomal DNA to upregulate genes involved in endothelial cell proliferation and vascular development. This action mirrors other intracrine factors, such as VEGF, which also regulate angiogenesis through nuclear localization.
Sources: en.wikipedia.org
=== Cytoskeleton associated functions === CK1δ is involved in the regulation of microtubule polymerization and stability of the spindle apparatus and centrosomes during mitosis by directly phosphorylating α-, β-, and γ-tubulin. Additionally, CK1δ can also phosphorylate microtubule-associated proteins (MAPs) thereby influencing their interaction with microtubules as well as microtubule dynamics.
== Extra reading == Habibullah, Mahmoud M; Mohan, Syam; Syed, Nabeel Kashan; Makeen, Hafiz A; Jamal, Qazi Mohammad Sajid; Alothaid, Hani; Bantun, Farkad; Alhazmi, Alaa; Hakamy, Ali; Kaabi, Yahia A; Samlan, Ghalia; Lohani, Mohtashim; Thangavel, Neelaveni; Al-Kasim, Mohamed Ahmed (June 2022). "Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells". Drug Design, Development and Therapy. 16: 1963–1974. doi:10.2147/DDDT.S367586. PMC 9249349. PMID 35783198.
== Types == Various patterns of measured patient temperatures have been observed, some of which may be indicative of a particular medical diagnosis: Continuous fever, where temperature remains above normal and does not fluctuate more than 1 °C in 24 hours (e.g. in bacterial pneumonia, typhoid fever, infective endocarditis, tuberculosis, or typhus). Intermittent fever is present only for a certain period, later cycling back to normal (e.g., in malaria, leishmaniasis, pyemia, sepsis, or African trypanosomiasis). Remittent fever, where the temperature remains above normal throughout the day and fluctuates more than 1 °C in 24 hours (e.g., in infective endocarditis or brucellosis). Pel–Ebstein fever is a cyclic fever that has been seen occasionally in patients with Hodgkin's lymphoma. Undulant fever, seen in brucellosis. Typhoid fever is a continuous fever showing a characteristic step-ladder pattern, a step-wise increase in temperature with a high plateau. Among the types of intermittent fever are ones specific to cases of malaria caused by different pathogens. These are:
Sources: en.wikipedia.org
By the mid-1990s, several GH companies had sponsored or publicized research into the quality of life of adults with severe GH deficiency. Most were people having been treated with GH in childhood for severe deficiency. Many of them stopped injections as they reached their final heights in the low-normal range. However, as adults in their 30s and 40s, these people, who had been children with growth hormone deficiency, were now adults with growth hormone deficiency and had more than their share of common adult problems: reduced physical, mental, and social energy, excess adipose and diminished muscle, diminished libido, poor bone density, higher cholesterol levels, and higher rates of cardiovascular disease. Research trials soon confirmed that a few months of GH could improve nearly all of these parameters. However, despite marketing efforts, most GH-deficient adults remain untreated. Though GH use was slow to be accepted among adults with GH deficiency, similar research to see if GH treatment could slow or reverse some of the similar effects of aging attracted much public interest. The most publicized trial was reported by Daniel Rudman in 1990. As with other types of hormone supplementation for aging (testosterone, estrogen, DHEA), confirmation of benefit and accurate understanding of risks has been only slowly evolving. In 1997, Ronald Klatz of the American Academy of Anti-Aging Medicine published Grow Young With HGH: The Amazing Medically Proven Plan To Reverse the Effects Of Aging, an uncritical touting of GH as the answer to aging.
A range for normal temperatures has been found. Central temperatures, such as rectal temperatures, are more accurate than peripheral temperatures. Fever is generally agreed to be present if the elevated temperature is caused by a raised set point and:
=== Microbiological uses === Quantitative PCR is also used by microbiologists working in the fields of food safety, food spoilage and fermentation and for the microbial risk assessment of water quality (drinking and recreational waters) and in public health protection. qPCR may also be used to amplify taxonomic or functional markers of genes in DNA taken from environmental samples. Markers are represented by genetic fragments of DNA or complementary DNA. By amplifying a certain genetic element, one can quantify the amount of the element in the sample prior to amplification. Using taxonomic markers (ribosomal genes) and qPCR can help determine the amount of microorganisms in a sample, and can identify different families, genera, or species based on the specificity of the marker. Using functional markers (protein-coding genes) can show gene expression within a community, which may reveal information about the environment.
George Oliver Gilham, First Secretary (Works), British High Commission, New Delhi. Joan Doreen Gol. For charitable and welfare services in Texas, United States of America. Rose Yin-chee Goodstadt, . For services to public health and welfare, Hong Kong. Louise Elizabeth Higham, Head, British Council Office, Barcelona. Marjone Helen Hoare. For services to literature and the island heritage, Gibraltar. Ann Hui On-wah. For services to the performing arts, Hong Kong. Norman Peter Jackson, Field Director, Save The Children Fund, Khartoum. Neil Alexander Kernohan, lately Vice-Consul, British Interests Section, Italian Embassy, Tripoli. James Kwan Kin-cheung. For public service, Hong Kong. Lee Lai-shan. For services to sport, Hong Kong. Andrew Leung Kwan-yuen. For services to the textile industry, Hong Kong. Leung Shou-chun, Principal Government Land Surveyor, Hong Kong. Li Shai-hung. For public service, Hong Kong. Simon Li Pak-ho, , Senior Assistant Director of Housing, Hong Kong. Sarah Mary Liao Sau-tung, . For services to consumer and environmental affairs, Hong Kong. Lo Tin-hoi, Management Assistant, British Trade Commission, Hong Kong. Dora Amy Logan. For services to the British community, Argentina. Fiona MacCallum, Attaché, HM Embassy, Riga. Allison Mary Marriott, lately Third Secretary, UK Delegation to the Western European Union, Brussels. Tanya Bonsovna Matthews. For services to broadcasting and journalism, Tunisia. Florenz Elaine Webbe Maxwell. For services to the Girl Guides and education in Bermuda.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.